This website uses cookies in order to provide you with the best possible user experience. To agree to our use of cookies, continue browsing as normal. Visit our Cookies Policy to learn more about the cookies we use and for information about how to change your preferences.
This website uses cookies in order to provide you with the best possible user experience. To agree to our use of cookies, continue browsing as normal. Visit our Cookies Policy to learn more about the cookies we use and for information about how to change your preferences.


Our strong professional & management teams consolidate Eurofins Amatsigroup into a leading CDMO

About Us

A strong track record in drug development services. A continuous integration of innovative technologies and capacities extension.


Years of experience


Competence Centers





Management Team


General Secretary Business School (ESCP)

Claire has a senior experience in supporting groups growth in integrating new activities and business acquisitions. Her background and skills cover controlling & accounting, project financing, IT, legal and management of support services. Claire will focus on IT including the ERP and integration of subsidiaries, structuring the core system while preserving agility and identity of each entity.


VP Business Development & Strategy Master Degree of Finance

Frédéric has 10 years+ experience within Life Science outsourcing industry through several managerial positions in Finance, Marketing, Strategy and Business Development across various global companies. Frédéric will focus on key strategic initiatives to support Amatsigroup international expansion: build up and M&A, alliances, partnerships and corporate development, and will bolster the company brand awareness.


Managing Director PhD, Biochem.Eng

Yves has 15 years of experience in pharmaceutical product development. He holds a Master’s degree in Biochemical Engineering. He obtained his PhD at Ghent University in Belgium where he pursued his research interests in the fields of pharmaceutical technology and pharmaceutical drug product development. In 2002 he started his professional career at Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson). In 2007 he founded SEPS Pharma specialized in drug product development. In 2015, Amatsigroup acquired his company. Ever since, he has managed Amatsigroup services in formulation development & manufacturing focusing on innovative technologies especially for bioavailiability enhancement or oral controlled release.

Our accreditations

We are committed to the highest quality and regulatory standards.

Our services are undertaken under a GLP (ANSM, ANSES) and GMP environment (ANSM, ANSES, FDA, PMDA, EMA).

We are accreditated by the French government for Research Tax Credit.

Our Clients


Amatsigroup achieved the process transfer of our injectable drug from a major industrial manufacturer and successfully managed the critical step of lyophilization. Amatsigroup has demonstrated its high adaptability to the manufacture of small batches suitable for the orphan drug market. To accommodate our expansion on the Japanese market, Amatsigroup’s team was very reactive and involved and got the Japanese PDMA accreditation within the expected timeframe.

Christophe Pasik, CEO

Keocyt SAS, A Riemser Group company

Amatsigroup is a very expertise based and science driven company focussing on the priorities of the sponsor/client. Over the last five to six years they evolved to  a well-balanced group of highly experienced, flexible and self-driving teams, invested in premises and equipment allowing them to cope with standard and specialty project requirements in the formulation and analytical domain for pre-clinical and clinical needs.

John Oliver, Head CMC Development

Major biotech company

Case Studies


  • NCE with very low solubility
  • Formulation and analytical development
  • Timelines of 12 months for FIH


  • API with very low solubility (BCS class IV)
  • High dose to be administered (0.1 to 1g dose for phase I)
  • Short timelines: 10 months from API reception to release of the clinical batch

Solutions oriented proposals

  • Screening of different formulation concepts (complexation, co-solvents, surfactants, aqueous nano-suspensions…) / Knowledge transfer to other Amatsigroup sites for manufacturing and GMP   analytics for selected formulation
  • Weekly calls with the client during complete duration of the project

Key successful outcomes

  • Formulation and analytical methods developed / One formulation selected for FIH
  • Technical batch and clinical batches produced / GMP analytics
  • Strong Project Management to avoid communication gaps and ensure on time delivery


  • European biotech company
  • Precipitation of material at low concentration at 5°C or 20°C
  • Aim for better stability and higher concentrations


  • Starting material difficult to handle due to material loss and aggregation
  • Provide a buffer for two monoclonal antibodies to be used as a combination product

Solutions oriented proposals

  • Project performed in 3 phases: screening for an optimal formulation buffer, formulation selection towards individual stability of the monoclonal antibodies and screening for an optimal formulation buffer for the two monoclonal antibodies as combination product
  • Selection based on internal stability data and predictions which were later confirmed by the client during long term stability studies

Key successful outcomes

  • The developed drug product is used for phase 1/2 clinical studies
  • Optimized formulation buffer was found for the combination product of the two monoclonal antibodies

Our partners


A technology provider for recombinant protein production, developing and optimizing microbial cell lines and processes for vaccines, biopharmaceuticals, biosimilars and enzymes

Aspe Conseil

A consulting firm specializing regulatory affairs, training and quality in the field of health products


A European CRO offering innovative chemistry, medicinal chemistry and process R&D services to accelerate the drug discovery and development process


Expert in pharmaceutical processes, pharmaceutical engineering and regulatory compliance, support for production and compliance projects, from design to inspection by regulatory authorities

Visit our other websites


Your message has been sent.

your name
your company,
your region
. I would like to discuss
select a topic
so please call me at
your phone number
or send an e-mail to
your e-mail address
leave your message.